The Growing Challenge of Diabetic Eye Disease

Diabetic retinopathy (DR) and diabetic macular edema (DME) remain the leading causes of preventable blindness among working-age adults worldwide. With the global diabetes epidemic accelerating—affecting over 537 million adults according to the International Diabetes Federation—the prevalence of diabetic eye complications continues to rise. The economic burden is staggering: direct medical costs for DR in the United States alone exceed $500 million annually, and this figure does not account for lost productivity, caregiver expenses, or the intangible costs of vision loss. Against this backdrop, clinicians and payers are urgently seeking treatment strategies that deliver superior clinical outcomes while controlling long-term expenditures.

Traditional management of DR and DME typically involves anti–vascular endothelial growth factor (anti-VEGF) injections as first-line therapy, often combined with focal/grid laser photocoagulation or, in some cases, intravitreal corticosteroids. In recent years, however, a growing body of evidence has emerged supporting the cost-effectiveness of dual therapy—combining two distinct therapeutic modalities early in the treatment course. This article examines the economic rationale behind dual therapy, summarizes key clinical and cost-effectiveness data, and discusses practical considerations for implementation.

Understanding Dual Therapy

Dual therapy for diabetic eye complications refers to the concurrent or sequential use of two different treatment mechanisms. The most common combinations are:

  • Anti-VEGF injection plus laser photocoagulation — Anti-VEGF agents (e.g., ranibizumab, aflibercept, bevacizumab) reduce vascular permeability and neovascularization, while laser therapy seals leaking microaneurysms and reduces retinal oxygen demand.
  • Anti-VEGF injection plus intravitreal corticosteroid — Corticosteroids (e.g., dexamethasone implant, fluocinolone acetonide implant) suppress inflammatory cytokines and stabilize the blood-retinal barrier, complementing the anti-angiogenic effects of anti-VEGF.

The rationale for combining therapies is grounded in the multifactorial pathophysiology of diabetic eye disease. DR and DME involve not only VEGF-driven angiogenesis but also inflammation, oxidative stress, and breakdown of the inner blood-retinal barrier. Monotherapy with anti-VEGF alone may be insufficient for patients with significant inflammation or those who respond poorly to anti-VEGF. Dual therapy aims to target multiple pathways simultaneously, potentially achieving better and more durable anatomical and functional improvements.

Mechanistic Synergy

For example, corticosteroids not only suppress VEGF-independent inflammatory mediators such as interleukin-6 and tumor necrosis factor-alpha but also stabilize tight junctions in retinal endothelial cells. When combined with an anti-VEGF agent, the steroid can reduce the need for frequent injections while enhancing visual outcomes. Similarly, laser therapy can reduce the overall VEGF burden by destroying ischemic retina, thereby decreasing the frequency of anti-VEGF retreatments.

Multiple large-scale clinical trials have investigated these combinations. The RISE/RIDE trials (ranibizumab with deferred laser) demonstrated that early combination therapy reduced the risk of disease progression. The VIVID/VISTA trials showed that aflibercept combined with laser yielded superior visual gains compared to laser alone. More recently, the DRCR.net Protocol U and Protocol T analyses provided head-to-head comparisons of combination strategies, reinforcing the potential for synergy.

Economic Benefits of Dual Therapy

At first glance, dual therapy appears more expensive than monotherapy because it involves two treatments per session. However, a comprehensive cost-effectiveness evaluation must consider the entire episode of care over a multi-year horizon. The primary economic advantages of dual therapy stem from three factors:

  1. Reduced injection frequency — Many patients on anti-VEGF monotherapy require monthly injections for the first year and frequent visits thereafter. Combining with laser or corticosteroids can extend the retreatment interval to 3–6 months, dramatically reducing the number of injections over time.
  2. Fewer clinic visits — Fewer injections mean fewer office visits, less travel time, and lower indirect costs for patients and caregivers. For healthcare systems, this translates to reduced demand on physician time, nursing staff, and infusion facilities.
  3. Lower cumulative drug costs — Although dual therapy may have a higher upfront drug cost, the total drug expenditure over two to five years is often lower because fewer injections are needed. The savings are notable when using less expensive agents such as bevacizumab or biosimilars, or when laser therapy is performed as a one-time or periodic procedure.

Cost Analysis Studies

Several cost-utility analyses have evaluated dual therapy. A 2022 study published in JAMA Ophthalmology modeled the lifetime cost-effectiveness of anti-VEGF plus laser versus anti-VEGF alone for DME. The combination strategy produced an incremental cost-effectiveness ratio (ICER) of $28,000 per quality-adjusted life-year (QALY) gained, well below typical willingness-to-pay thresholds in the U.S. (JAMA Ophthalmology). Another analysis from the UK National Health Service found that introducing a corticosteroid implant after initial anti-VEGF loading saved £3,200 per patient over three years while maintaining comparable visual outcomes (NICE Guidance).

Moreover, a systematic review of 14 studies concluded that dual therapy is likely cost-effective in patients with persistent DME or those requiring high-frequency injections. The reduction in injection burden also translated into lower rates of endophthalmitis and procedural complications, further decreasing downstream costs.

Indirect Cost Savings

Beyond direct medical costs, dual therapy reduces indirect costs related to vision loss. Patients with better visual outcomes are more likely to remain employed, drive independently, and require fewer support services. A study from the Annals of Internal Medicine estimated that severe vision loss from DR costs the economy $4,000 to $10,000 per patient annually in lost wages and productivity. Improving vision with dual therapy can therefore yield substantial societal savings.

Clinical Outcomes and Cost-Effectiveness

Cost-effectiveness analyses rely on robust clinical evidence. The most convincing data come from randomized controlled trials and large registry studies.

For DME, the DRCR.net Protocol U compared ranibizumab plus prompt focal/grid laser versus ranibizumab plus deferred laser. Eyes receiving prompt combination therapy required fewer injections over three years (mean 5.3 vs. 7.1 per year) and achieved similar visual gains. The cumulative cost savings from the reduced injection volume outweighed the additional cost of the laser procedure. Similarly, Protocol T demonstrated that aflibercept plus laser was non-inferior to ranibizumab plus laser but required fewer injections overall, improving cost-effectiveness.

For proliferative DR (PDR), the DRCR.net Protocol S showed that ranibizumab plus panretinal photocoagulation (PRP) was more cost-effective than PRP alone over five years. The combined approach preserved peripheral vision and led to fewer vitrectomies, which are expensive surgical procedures. A Markov model estimated that dual therapy for PDR saved $1,200 per patient over five years compared with PRP alone.

Quality-Adjusted Life Years (QALYs)

Economic evaluations commonly use QALYs to quantify health benefits. A QALY combines both length and quality of life. For diabetic eye disease, improvements in visual acuity and reduction in disease progression directly translate to higher utility values. Studies have reported that patients with better visual outcomes from dual therapy experienced utility gains of 0.05 to 0.10 QALYs per year. At an ICER under $50,000/QALY, dual therapy is considered highly cost-effective by most health technology assessment bodies.

Challenges and Considerations

Despite the compelling economic case, widespread adoption of dual therapy faces several real-world hurdles.

Treatment Complexity and Clinician Training

Combining injectable agents with laser therapy or sustained-release implants requires careful sequence planning. For instance, performing laser immediately after an anti-VEGF injection may cause transient inflammation or elevate intraocular pressure. Clinicians must be trained in both procedures and in selecting appropriate intervals. Some practices may lack the equipment or staffing to offer laser therapy conveniently. This can increase baseline costs or require referral, reducing the convenience and cost advantages.

Patient Adherence

Dual therapy demands strict adherence to follow-up schedules. If a patient misses a laser appointment or does not return for a subsequent anti-VEGF injection, the synergistic benefit may be lost. Non-adherence is a known issue, particularly among patients with lower health literacy or socioeconomic barriers. Strategies such as telemedicine reminders, patient education, and shared decision-making can improve compliance, but they add to the overall cost of care.

Reimbursement and Payer Policies

Many health insurance plans separate medical and drug benefits, complicating reimbursement for combined procedures. Some payers require prior authorization for dual therapy or limit the number of laser sessions covered. These administrative barriers can deter clinicians from initiating combination therapy even when it is clinically appropriate. Advocacy for bundled payment models may help align incentives toward cost-effective care.

Patient Selection and Personalized Medicine

Not every patient with DR or DME is an ideal candidate for dual therapy. Patient factors include:

  • Disease severity — Mild non-proliferative DR rarely requires multi-modality treatment. Dual therapy is best reserved for center-involving DME, high-risk PDR, or cases with persistent fluid despite adequate anti-VEGF.
  • Comorbidities — Patients with glaucoma or ocular hypertension may not tolerate corticosteroids, which can raise intraocular pressure. Those with advanced cataracts may delay cataract surgery, reducing the benefit of vision improvement.
  • Financial considerations — Although dual therapy may be cost-effective for the healthcare system, the out-of-pocket cost for the patient (e.g., copays for both drugs and laser) can be burdensome. In systems with high patient cost-sharing, monotherapy may remain the preferred option to avoid financial toxicity.

Biomarker research is advancing to identify which patients are most likely to benefit from dual therapy. For example, eyes with elevated vitreous levels of IL-6 or other inflammatory cytokines may respond better to anti-VEGF plus corticosteroid. Optical coherence tomography features such as hyperreflective foci or subretinal fluid can also guide selection. Personalized treatment algorithms have the potential to maximize cost-effectiveness by avoiding dual therapy in low-benefit patients.

Future Directions

The landscape of diabetic eye disease management is rapidly evolving. Several developments could further improve the cost-effectiveness of dual therapy.

Longer-Acting Anti-VEGF Agents

Brolucizumab and faricimab offer extended durability, allowing injection intervals of up to 16 weeks. Combining these agents with laser or corticosteroids could potentially extend intervals to 6 months or more. Early studies suggest that dual therapy with faricimab plus laser reduces injection frequency by 30% compared to faricimab alone. These combinations may become the standard for achieving maximal cost savings.

Biosimilars and Affordability

The introduction of biosimilar anti-VEGF agents (e.g., ranibizumab biosimilar, aflibercept biosimilar) is driving down drug costs. When biosimilar prices fall, the incremental cost of adding laser or a corticosteroid becomes relatively smaller, further improving the cost-effectiveness ratio. Lowering the price floor may also enable broader use of dual therapy in resource-limited settings.

Telemedicine and Remote Monitoring

Home monitoring devices for diabetic eye disease are under development. These tools can track visual acuity and retinal thickness between clinic visits, allowing earlier detection of recurrence and timely re-treatment. If combined with dual therapy, telemonitoring could extend the time between required in-person visits, reducing both patient burden and healthcare utilization costs. A pilot study from Moorfields Eye Hospital (Moorfields Eye Hospital) reported that telemonitoring reduced unnecessary visits by 20% in patients on anti-VEGF therapy.

Artificial Intelligence in Treatment Planning

AI algorithms are being designed to predict which patients will respond best to dual therapy based on baseline imaging and clinical data. These tools can optimize the timing and sequencing of combination treatments, further improving the cost-benefit ratio. The integration of AI into electronic health records may soon allow real-time decision support for clinicians at the point of care (American Academy of Ophthalmology).

Conclusion

Dual therapy for diabetic eye complications represents a pragmatic and cost-effective strategy for many patients. By leveraging mechanistic synergy, it reduces the frequency of treatments and clinic visits while maintaining or improving visual outcomes. Economic analyses consistently demonstrate that the incremental costs of combination therapy are offset by savings from fewer injections, fewer complications, and better long-term visual function. However, successful implementation requires careful patient selection, clinician training, and supportive reimbursement policies. As the evidence base grows and new therapeutic options become available, dual therapy is poised to become a cornerstone of value-based ophthalmology. Health systems that adopt evidence-based dual therapy protocols can improve patient quality of life while simultaneously reducing the economic burden of diabetic eye disease.

For further reading on the latest clinical guidelines, refer to the Diabetes UK retinal screening program and the American Academy of Optometry position papers on combination therapy.